Skip to main content
. Author manuscript; available in PMC: 2018 Aug 17.
Published in final edited form as: Mol Cell. 2017 Aug 10;67(4):685–701.e6. doi: 10.1016/j.molcel.2017.07.014

Figure 6. PON2 inhibits FOXO3-mediated induction of PUMA transcription to promote tumor growth and anoikis resistance.

Figure 6

A. Subcutaneous tumor formation in athymic nude mice following injections of PANC1 cells carrying the indicated shRNAs. B. Anoikis assay measuring the proliferation of PANC1 cells carrying the indicated shRNAs in poly(HEMA)-coated plates. Live cell counts on the indicated days are shown. C. Immunoblot assay to measure PARP cleavage in PANC1 cells carrying the indicated shRNAs. D. Lung metastasis imaging following tail veil injection of luciferase-tagged PANC1 cells carrying the indicated shRNAs in athymic nude mice (n=3). Bioluminescence images at week 1 and week 4 under indicated conditions are shown. E. Immunoblot analysis to measure phosphorylated AMPK levels in PANC1 cells expressing PON2 or nonspecific (NS) shRNAs in DMEM supplemented with the indicated concentrations of glucose (top) or 10 mM pyruvate or succinate (Bottom). Total AMPK was used as a control. F. Soft-agar colony formation by PANC1 cell lines expressing PON2 shRNA or NS shRNA (left) grown in regular DMEM with 25 mM or 75 mM glucose. Data are presented as mean ± SEM. *p<0.05, **p<0.005. See also Figure S7 and Table S2.